Compare Stocks: CNTX, ACIU, CHRS, and TARA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.29 +0.9%	$2.38	$2.03 ▼ $4.00	$231.03M	1.59	186,723 shs	145,047 shs
CHRS Coherus Oncology	$1.45 -2.0%	$1.47	$0.81 ▼ $2.62	$228.29M	0.98	599,673 shs	992,580 shs
CNTX Context Therapeutics	$0.69 +11.5%	$0.95	$0.55 ▼ $3.62	$57.13M	1.74	2.29 million shs	2.32 million shs
TARA Protara Therapeutics	$4.00 -0.2%	$4.08	$2.97 ▼ $7.82	$225.38M	1.5	434,634 shs	480,602 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+2.25%	-2.16%	-9.56%	-23.57%	+3.65%
CHRS Coherus Oncology	+2.78%	+2.78%	+2.07%	-15.43%	+70.51%
CNTX Context Therapeutics	+2.93%	+5.28%	-4.88%	-74.20%	-8.56%
TARA Protara Therapeutics	+1.01%	+1.78%	-1.23%	-29.15%	+26.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.29 +0.9%	$2.38	$2.03 ▼ $4.00	$231.03M	1.59	186,723 shs	145,047 shs
CHRS Coherus Oncology	$1.45 -2.0%	$1.47	$0.81 ▼ $2.62	$228.29M	0.98	599,673 shs	992,580 shs
CNTX Context Therapeutics	$0.69 +11.5%	$0.95	$0.55 ▼ $3.62	$57.13M	1.74	2.29 million shs	2.32 million shs
TARA Protara Therapeutics	$4.00 -0.2%	$4.08	$2.97 ▼ $7.82	$225.38M	1.5	434,634 shs	480,602 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+2.25%	-2.16%	-9.56%	-23.57%	+3.65%
CHRS Coherus Oncology	+2.78%	+2.78%	+2.07%	-15.43%	+70.51%
CNTX Context Therapeutics	+2.93%	+5.28%	-4.88%	-74.20%	-8.56%
TARA Protara Therapeutics	+1.01%	+1.78%	-1.23%	-29.15%	+26.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.40	Hold	$7.50	227.51% Upside
CHRS Coherus Oncology	2.75	Moderate Buy	$8.67	497.70% Upside
CNTX Context Therapeutics	2.89	Moderate Buy	$6.17	789.85% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	556.25% Upside

Current Analyst Ratings Breakdown

Latest CNTX, ACIU, CHRS, and TARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/17/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/16/2026	CNTX Context Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $4.00
5/20/2026	TARA Protara Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$25.00 ➝ $28.00
5/20/2026	TARA Protara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
5/20/2026	TARA Protara Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/20/2026	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	TARA Protara Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $26.00
5/13/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$4.31M	54.07	N/A	N/A	$0.54 per share	4.24
CHRS Coherus Oncology	$42.17M	5.30	N/A	N/A	$0.50 per share	2.90
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.82	N/A	13.47	N/A	-1,788.02%	-125.26%	-40.85%	N/A
CHRS Coherus Oncology	$168.02M	$1.67	0.87	N/A	N/A	397.30%	-198.90%	-46.65%	8/5/2026 (Estimated)
CNTX Context Therapeutics	-$36.12M	-$0.42	N/A	N/A	N/A	N/A	-59.95%	-54.78%	8/5/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.34	N/A	N/A	N/A	N/A	-38.70%	-36.02%	8/10/2026 (Estimated)

Latest CNTX, ACIU, CHRS, and TARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	ACIU AC Immune	$0.1214	$0.03	-$0.0914	$0.03	$34.08 million	$18.67 million
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.2450	-$0.19	+$0.0550	-$0.13	$14.41 million	$14.31 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.10	-$0.15	-$0.05	-$0.15	N/A	N/A
5/13/2026	Q1 2026	TARA Protara Therapeutics	-$0.36	-$0.31	+$0.05	-$0.31	N/A	N/A
5/11/2026	Q1 2026	CHRS Coherus Oncology	-$0.2633	-$0.25	+$0.0133	-$0.28	$14.22 million	$12.31 million
5/6/2026	Q1 2026	CNTX Context Therapeutics	-$0.12	-$0.09	+$0.03	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.87	1.02
CHRS Coherus Oncology	0.47	1.56	1.52
CNTX Context Therapeutics	N/A	8.96	8.96
TARA Protara Therapeutics	N/A	15.69	15.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CHRS Coherus Oncology	72.82%
CNTX Context Therapeutics	14.03%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CHRS Coherus Oncology	7.22%
CNTX Context Therapeutics	4.80%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	101.77 million	97.09 million	Optionable
CHRS Coherus Oncology	330	154.25 million	143.11 million	Optionable
CNTX Context Therapeutics	7	91.88 million	87.47 million	Not Optionable
TARA Protara Therapeutics	30	56.20 million	51.93 million	Optionable

CNTX, ACIU, CHRS, and TARA Headlines

Recent News About These Companies

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages

August 4 at 2:13 AM | marketbeat.com

Protara Therapeutics (TARA) Projected to Announce Quarterly Earnings on Monday

August 3 at 10:10 AM | marketbeat.com

Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA

July 24, 2026 | marketbeat.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Moderate Buy" by Brokerages

July 10, 2026 | marketbeat.com

AIGH Capital Management LLC Takes Position in Protara Therapeutics, Inc. $TARA

July 9, 2026 | marketbeat.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of ...

May 15, 2026 | markets.businessinsider.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

May 15, 2026 | globenewswire.com

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

May 13, 2026 | globenewswire.com

One Protara Therapeutics Insider Raised Their Stake In The Previous Year

May 4, 2026 | finance.yahoo.com

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...

April 28, 2026 | markets.businessinsider.com

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

April 27, 2026 | globenewswire.com

Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) Stock

April 3, 2026 | insidertrades.com

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

March 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, ACIU, CHRS, and TARA Company Descriptions

AC Immune NASDAQ:ACIU

$2.29 +0.02 (+0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$2.30 +0.00 (+0.22%)

As of 07:34 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Coherus Oncology NASDAQ:CHRS

$1.45 -0.03 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 -0.07 (-4.83%)

As of 07:39 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Context Therapeutics NASDAQ:CNTX

$0.69 +0.07 (+11.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.48 -0.22 (-31.17%)

As of 07:59 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Protara Therapeutics NASDAQ:TARA

$4.00 -0.01 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 -0.02 (-0.50%)

As of 07:34 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTX, ACIU, CHRS, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTX, ACIU, CHRS, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTX, ACIU, CHRS, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, ACIU, CHRS, and TARA Company Descriptions

AC Immune NASDAQ:ACIU

Coherus Oncology NASDAQ:CHRS

Context Therapeutics NASDAQ:CNTX

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTX, ACIU, CHRS, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTX, ACIU, CHRS, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTX, ACIU, CHRS, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, ACIU, CHRS, and TARA Company Descriptions

AC Immune NASDAQ:ACIU

Coherus Oncology NASDAQ:CHRS

Context Therapeutics NASDAQ:CNTX

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools